STOCK TITAN

Maravai LifeSciences Announces March 2021 Investor Conference Schedule

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

SAN DIEGO, March 01, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in two upcoming virtual investor conferences.

On March 3, 2021, Carl Hull, Chief Executive Officer, is scheduled to present at the Cowen Health Care Conference at 10:20 a.m. PT.

On March 23, 2021, Hull will participate in a fireside chat at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum at 8:30 a.m. PT.

A live webcast of the presentations will be available to all interested parties on the Maravai Lifesciences investor relations website at http://investors.maravai.com. An archived version of the webcast will be available a few hours following the completion of each event on the Maravai investor relations website.

About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis, bioprocess impurity detection and analysis, and protein labeling and detection to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.

For more information about Maravai LifeSciences, visit www.maravai.com.


Maravai LifeSciences Holdings Inc

NASDAQ:MRVI

MRVI Rankings

MRVI Latest News

MRVI Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Commercial Services, Miscellaneous Commercial Services
US
San Diego

About MRVI

maravai lifesciences catalyzes the growth of successful, entrepreneurial life science companies by providing expertise, capital, processes and systems so that they can continue to serve scientists who are striving to improve human health. current maravai lifesciences portfolio companies provide enabling tools and services in the life sciences research and bioproduction industries that accelerate breakthrough discoveries in areas such as genomics, proteomics, and biotherapeutic development. maravai lifesciences was formed in march 2014 through a partnership with gtcr, a leading private equity firm. our mission is to build a transformative life sciences reagents company by acquiring outstanding businesses and accelerating their growth. since our founding, we have acquired four companies, each a leader in its market segment. vector laboratories has led the market for labeling and detection products used by researchers in immunohistochemistry, immunofluorescence and related techniques. tri